Literature DB >> 2167946

Acute haemorrhagic conjunctivitis: seroepidemiology of coxsackievirus A24 variant and enterovirus 70 in Singapore.

K T Goh1, P L Ooi, K Miyamura, T Ogino, S Yamazaki.   

Abstract

Epidemics of acute haemorrhagic conjunctivitis caused by a variant of coxsackievirus A24 (CA24v) and enterovirus 70 (EV70) have occurred periodically in Singapore. A seroepidemiological survey conducted before the CA24v epidemic in 1985 and in the midst of the EV70 epidemic in 1983 showed a neutralising antibody prevalence (greater than or equal to 1:4) of 19.1% and 66.9% to CA24v and EV70, respectively. The seropositivity rate to both viruses was highest in children 10-14 years of age, but no sex or ethnic difference was noted. It appears from the data that an epidemic could be triggered when the herd immunity of the population falls below a critical level. There was a significant correlation in seroprevalence between CA24v and EV70 (P = 7.75 x 10(-3).

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2167946     DOI： 10.1002/jmv.1890310313

Source DB:  PubMed          Journal:  J Med Virol        ISSN： 0146-6615            Impact factor:   2.327


  9 in total

1.  Molecular epidemiology of a variant of coxsackievirus A24 in Taiwan: two epidemics caused by phylogenetically distinct viruses from 1985 to 1989.

Authors:  K H Lin; H L Wang; M M Sheu; W L Huang; C W Chen; C S Yang; N Takeda; N Kato; K Miyamura; S Yamazaki
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

2.  Phylogenetically different strains of a variant of coxsackievirus A 24 were repeatedly introduced but discontinued circulating in Japan.

Authors:  H Ishiko; N Takeda; K Miyamura; M Tanimura; T Yamanaka; K Kasuga; K Oda; K Imai; Y Yamamoto; Y Mochida
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 3.  The epidemiology of non-polio enteroviruses: recent advances and outstanding questions.

Authors:  Margarita Pons-Salort; Edward P K Parker; Nicholas C Grassly
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

4.  Detection of non-polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines.

Authors:  Lea Necitas Apostol; Akira Suzuki; Analisa Bautista; Hazel Galang; Fem Julia Paladin; Naoko Fuji; Socorro Lupisan; Remigio Olveda; Hitoshi Oshitani
Journal:  J Med Virol       Date:  2012-04       Impact factor: 2.327

5.  Genetic diversity and molecular characterization of enteroviruses from sewage-polluted urban and rural rivers in the Philippines.

Authors:  Lea Necitas G Apostol; Tomifumi Imagawa; Akira Suzuki; Yoshifumi Masago; Socorro Lupisan; Remigio Olveda; Mariko Saito; Tatsuo Omura; Hitoshi Oshitani
Journal:  Virus Genes       Date:  2012-06-29       Impact factor: 2.332

6.  Phylogenetic and molecular characterization of coxsackievirus A24 variant isolates from a 2010 acute hemorrhagic conjunctivitis outbreak in Guangdong, China.

Authors:  Wu De; Zheng Huanying; Li Hui; Monagin Corina; Guo Xue; Liu Leng; Zeng Hanri; Fang Ling; Mo Yanling; Zhou Huiqiong; Zhang Huan; Kou Jing; Long Caiyun; Hiromu Yoshida; Ke Changwen
Journal:  Virol J       Date:  2012-02-15       Impact factor: 4.099

7.  Acute hemorrhagic conjunctivitis: anti-coxsackievirus A24 variant secretory immunoglobulin A in acute and convalescent tear.

Authors:  Marlyn P Langford; Edwin A Anders; Maxwell A Burch
Journal:  Clin Ophthalmol       Date:  2015-09-10

8.  Acute hemorrhagic conjunctivitis caused by coxsackievirus A24 variant, South Korea, 2002.

Authors:  Myoung-don Oh; Sangwon Park; Youngju Choi; Hongbin Kim; Kiduk Lee; Wanbum Park; Youngae Yoo; Eui-Chong Kim; Kangwon Choe
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

9.  Molecular evolution of coxsackievirus A24v in Cuba over 23-years, 1986-2009.

Authors:  Magilé C Fonseca; Mario Pupo-Meriño; Luis A García-González; Sonia Resik; Lai Heng Hung; Mayra Muné; Hermis Rodríguez; Luis Morier; Heléne Norder; Luis Sarmiento
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.